Navigating Psychedelic Medicines through (Inter)national Regulation

    Research output: Contribution to conferenceOtherpeer-review

    Abstract

    Clinical trials using psychedelic substances such as MDMA, marijuana, ketamine and psilocybin to combat mental and physical illnesses can only commence after years of regulatory and ethical hurdle-leaping and face many more before those medicines may be licensed. The impact of the classification of psychedelic substances as having no accepted medical use on the regulatory systems governing clinical research and licensing in the US, Europe and the UK will be considered and possible solutions to the legal impasse will be offered.
    Original languageEnglish
    Publication statusPublished - 2 Jul 2017
    EventBreaking Convention 2017 - London
    Duration: 2 Jul 2017 → …

    Conference

    ConferenceBreaking Convention 2017
    Period2/07/17 → …

    Fingerprint Dive into the research topics of 'Navigating Psychedelic Medicines through (Inter)national Regulation'. Together they form a unique fingerprint.

    Cite this